In addition, apoB is better as a target in patients with mild to moderate hypertriglyceridemia (175–880 mg/dL), diabetes, obesity or metabolic syndrome [116]. This evidence concerns the gene APOB and obesity due to melanocortin 4 receptor deficiency.